

# Haesook T Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9522025/publications.pdf>

Version: 2024-02-01

111  
papers

6,723  
citations

145106

33  
h-index

71088

80  
g-index

112  
all docs

112  
docs citations

112  
times ranked

9329  
citing authors

#	ARTICLE	IF	CITATIONS
1	Donor Clonal Hematopoiesis and Recipient Outcomes After Transplantation. <i>Journal of Clinical Oncology</i> , 2022, 40, 189-201.	0.8	79
2	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. <i>Blood Advances</i> , 2022, 6, 2183-2194.	2.5	12
3	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	48
4	Phenotypic and functional characterization of the CD6-ALCAM T-cell co-stimulatory pathway after allogeneic cell transplantation. <i>Haematologica</i> , 2022, 107, 2617-2629.	1.7	2
5	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. <i>Bone Marrow Transplantation</i> , 2021, 56, 1006-1012.	1.3	15
6	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2021, 5, 352-364.	2.5	58
7	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. <i>Blood Advances</i> , 2021, 5, 861-871.	2.5	23
8	Allogeneic hematopoietic cell transplantation outcomes in patients with Richter's transformation. <i>Haematologica</i> , 2021, 106, 3219-3222.	1.7	15
9	Novel Composite Endpoints after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 650-657.	0.6	6
10	Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution. <i>Blood Advances</i> , 2021, 5, 5140-5149.	2.5	21
11	Phase II Clinical Trial of Abatacept for Steroid-Refractory Chronic Graft Versus Host Disease. <i>Blood</i> , 2021, 138, 264-264.	0.6	3
12	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. <i>Blood Advances</i> , 2020, 4, 4113-4123.	2.5	22
13	A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. <i>Blood</i> , 2020, 135, 2182-2191.	0.6	62
14	BK virus-specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2020, 4, 1881-1893.	2.5	16
15	Peripheral host T cells survive hematopoietic stem cell transplantation and promote graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2020, 130, 4624-4636.	3.9	55
16	<sc>MYD</sc>88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in <sc>CLL</sc>. <i>British Journal of Haematology</i> , 2019, 184, 925-936.	1.2	18
17	Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2019, 6, e419-e428.	2.2	60
18	Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. <i>Clinical Cancer Research</i> , 2019, 25, 5143-5155.	3.2	10

#	ARTICLE	IF	CITATIONS
19	Reactivation of BK virus after double umbilical cord blood transplantation in adults correlates with impaired reconstitution of CD4+ and CD8+ T effector memory cells and increase of T regulatory cells. <i>Clinical Immunology</i> , 2019, 207, 18-23.	1.4	10
20	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem Cell Transplantation: An Ancillary Analysis of a Randomized Controlled Trial Comparing Tacrolimus/Sirolimus and Tacrolimus/Methotrexate (Blood and Marrow Transplant Clinical Trials) Tj ETQq0 0 0 rgBT70verlock 10 Tf 50 6	2.0	15
21	Dose-escalated interleukin-2 therapy for refractory chronic graft-versus-host disease in adults and children. <i>Blood Advances</i> , 2019, 3, 2550-2561.	2.5	44
22	Functional analysis of clinical response to low-dose IL-2 in patients with refractory chronic graft-versus-host disease. <i>Blood Advances</i> , 2019, 3, 984-994.	2.5	24
23	Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. <i>Blood Advances</i> , 2019, 3, 1167-1174.	2.5	23
24	Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1â€“1b study. <i>Lancet Haematology</i> , 2019, 6, e38-e47.	2.2	98
25	Ofatumumab plus high dose methylprednisolone followed by ofatumumab plus alemtuzumab to achieve maximal cyto-reduction prior to allogeneic transplantation for 17p deleted or TP53 mutated chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1312-1315.	0.6	3
26	Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease. <i>Blood</i> , 2018, 131, 2836-2845.	0.6	30
27	A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1733-1740.	2.0	23
28	Minimal residual disease detected by immunoglobulin sequencing predicts CLL relapse more effectively than flow cytometry. <i>Leukemia and Lymphoma</i> , 2018, 59, 1986-1989.	0.6	4
29	Effect of Antihuman T Lymphocyte Globulin on Immune Recovery after Myeloablative Allogeneic Stem Cell Transplantation with Matched Unrelated Donors: Analysis of Immune Reconstitution in a Double-Blind Randomized Controlled Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2216-2223.	2.0	18
30	Impact of Thrombotic Microangiopathy on Renal Outcomes and Survival after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2344-2353.	2.0	37
31	Effect of Sirolimus on Immune Reconstitution Following Myeloablative Allogeneic Stem-Cell Transplantation: A Post-Hoc Analysis of a Randomized Controlled Trial Comparing Sirolimus/Tacrolimus with Tacrolimus/Methotrexate (BMT CTN 0402). <i>Blood</i> , 2018, 132, 2110-2110.	0.6	1
32	A Phase I/II Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation (alloHCT). <i>Blood</i> , 2018, 132, 705-705.	0.6	10
33	Incidence and Predictors of Hepatic Veno-Occlusive Disease after Reduced Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 3376-3376.	0.6	0
34	Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. <i>Blood</i> , 2017, 129, 1380-1388.	0.6	209
35	PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy. <i>Blood</i> , 2017, 129, 2186-2197.	0.6	156
36	Venous thromboembolism is associated with graft-versus-host disease and increased non-relapse mortality after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2017, 102, 1185-1191.	1.7	31

#	ARTICLE	IF	CITATIONS
37	Antibodies targeting surface membrane antigens in patients with chronic graft-versus-host disease. <i>Blood</i> , 2017, 130, 2889-2899.	0.6	17
38	Angiogenic Factors Correlate with T Cell Immune Reconstitution and Clinical Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 103-112.	2.0	4
39	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. <i>Clinical Cancer Research</i> , 2017, 23, 735-745.	3.2	74
40	Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 4003-4011.	0.8	258
41	Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells. <i>JCI Insight</i> , 2016, 1, e89278.	2.3	126
42	Donor and recipient sex in allogeneic stem cell transplantation: what really matters. <i>Haematologica</i> , 2016, 101, 1260-1266.	1.7	54
43	The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. <i>British Journal of Haematology</i> , 2016, 173, 96-104.	1.2	53
44	Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. <i>Blood</i> , 2016, 127, 646-657.	0.6	145
45	Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. <i>Blood</i> , 2016, 128, 130-137.	0.6	176
46	Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. <i>Blood</i> , 2016, 128, 195-203.	0.6	259
47	An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2084-2091.	2.0	16
48	A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation. <i>Haematologica</i> , 2016, 101, 1251-1259.	1.7	27
49	Next-generation sequencing-based detection of circulating tumour DNA After allogeneic stem cell transplantation for lymphoma. <i>British Journal of Haematology</i> , 2016, 175, 841-850.	1.2	47
50	Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent. <i>Blood</i> , 2016, 128, 1845-1853.	0.6	83
51	Circulating T follicular helper cells with increased function during chronic graft-versus-host disease. <i>Blood</i> , 2016, 127, 2489-2497.	0.6	92
52	Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients. <i>Blood</i> , 2016, 128, 3243-3243.	0.6	15
53	A Prospective Randomized Double Blind Phase 3 Clinical Trial of Anti-T Lymphocyte Globulin (ATLG) to Assess Impact on Chronic Graft-Versus-Host Disease (cGVHD) Free Survival in Patients Undergoing HLA Matched Unrelated Myeloablative Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2016, 128, 505-505.	0.6	12
54	TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. <i>Blood</i> , 2016, 128, 641-641.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Bortezomib-Based Versus Standard of Care Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation: A Phase II Randomized Controlled Trial. <i>Blood</i> , 2016, 128, 508-508.	0.6	3
56	BK Virus-Specific T Cell Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 3425-3425.	0.6	0
57	Functional Effects of Low-Dose IL-2 in Patients with Chronic Graft Versus Host Disease. <i>Blood</i> , 2016, 128, 667-667.	0.6	4
58	High $^{125}\text{I}$ Np73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia. <i>Blood</i> , 2015, 126, 2302-2306.	0.6	28
59	Efficacy of immune suppression tapering in treating relapse after reduced intensity allogeneic stem cell transplantation. <i>Haematologica</i> , 2015, 100, 1222-1227.	1.7	24
60	Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 873-880.	2.0	56
61	Angiogenic Cytokines Are Antibody Targets During Graft-versus-Leukemia Reactions. <i>Clinical Cancer Research</i> , 2015, 21, 1010-1018.	3.2	11
62	Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) after Treatment with Programmed Cell Death 1 (PD-1) Inhibitors. <i>Blood</i> , 2015, 126, 2018-2018.	0.6	5
63	Antigen Level Matching at HLA-C Improves Long-Term Outcomes after Double Umbilical Cord Blood Transplantation. <i>Blood</i> , 2015, 126, 2022-2022.	0.6	1
64	Comprehensive Genetic Characterization of 17p Deleted CLL Identifies Predictors of Overall Survival. <i>Blood</i> , 2015, 126, 2907-2907.	0.6	1
65	Sequencing-Based Detection of Circulating Tumor DNA in the Autologous Stem Cell Grafts of Patients with Diffuse Large B-Cell Lymphoma Undergoing Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 3156-3156.	0.6	2
66	Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL. <i>Blood</i> , 2015, 126, 4158-4158.	0.6	9
67	A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL. <i>Blood</i> , 2015, 126, 4159-4159.	0.6	1
68	Idelalisib Given Front-Line for the Treatment of Chronic Lymphocytic Leukemia Results in Frequent and Severe Immune-Mediated Toxicities. <i>Blood</i> , 2015, 126, 497-497.	0.6	21
69	Double Expressing (MYC/BCL2) and Double-Hit Diffuse Large B-Cell Lymphomas Have Inferior Survival Following Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 522-522.	0.6	3
70	A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 860-860.	0.6	5
71	IL-7 and SCF Levels Inversely Correlate with T Cell Reconstitution and Clinical Outcomes after Cord Blood Transplantation in Adults. <i>PLoS ONE</i> , 2015, 10, e0132564.	1.1	22
72	MYD88 L265P Mutations Influence Clinical Outcome and Identify a Pathway for Targeted Inhibition in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 491-491.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Long-Term Homeostatic Effects of Daily Low-Dose IL-2 on CD4+ FoxP3+ Regulatory T Cells in Patients with Active Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2015, 126, 3133-3133.	0.6	0
74	Venous Thromboembolism Is Associated with Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 742-742.	0.6	0
75	Increased mitochondrial apoptotic priming of human regulatory T cells after allogeneic hematopoietic stem cell transplantation. <i>Haematologica</i> , 2014, 99, 1499-1508.	1.7	15
76	Iron Overload in Allogeneic Hematopoietic Cell Transplantation Outcome: A Meta-Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1248-1251.	2.0	64
77	White blood cell recovery after allogeneic hematopoietic cell transplantation predicts clinical outcome. <i>American Journal of Hematology</i> , 2014, 89, 591-597.	2.0	19
78	A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1737-1743.	2.0	48
79	Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 668-675.	2.0	45
80	Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1516-1521.	2.0	50
81	Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. <i>Blood</i> , 2014, 123, 3664-3671.	0.6	730
82	Enhanced Expression of PD-1 Modulates CD4+Foxp3+ Regulatory T Cell Homeostasis during Low-Dose IL-2 Therapy in Patients with Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2014, 124, 662-662.	0.6	0
83	Immunosuppression Taper to Induce Graft-Verus-Tumor Activity As the Sole Therapy for Early Relapse after Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2014, 124, 2504-2504.	0.6	0
84	Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 860-866.	2.0	17
85	Low-Dose Interleukin-2 Therapy Restores Regulatory T Cell Homeostasis in Patients with Chronic Graft-Versus-Host Disease. <i>Science Translational Medicine</i> , 2013, 5, 179ra43.	5.8	401
86	The Addition Of Sirolimus To The Gvhd Prophylaxis Regimen In Reduced Intensity Allogeneic Stem Cell Transplantation For Lymphoma: A Multicenter Randomized Trial. <i>Blood</i> , 2013, 122, 704-704.	0.6	3
87	A disease risk index for patients undergoing allogeneic stem cell transplantation. <i>Blood</i> , 2012, 120, 905-913.	0.6	310
88	A Phase I Study of Alemtuzumab Dosing for Steroid-Refractory Chronic Graft-Versus-Host Disease. <i>Blood</i> , 2012, 120, 744-744.	0.6	0
89	Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2012, 120, 3069-3069.	0.6	5
90	Prognostic Factors for Patients with Diffuse Large B Cell Lymphoma and Transformed Indolent Lymphoma Undergoing Autologous Stem Cell Transplantation in the PET Era. <i>Blood</i> , 2012, 120, 1980-1980.	0.6	0

#	ARTICLE	IF	CITATIONS
91	Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease. <i>New England Journal of Medicine</i> , 2011, 365, 2055-2066.	13.9	996
92	Response to Helsby and Tingle. <i>American Journal of Hematology</i> , 2011, 86, 384-384.	2.0	1
93	Reply to induction therapy and outcome in acute myeloid leukemia. <i>Cancer</i> , 2011, 117, 2237-2237.	2.0	1
94	Does Iron Overload Really Matter in Stem Cell Transplantation?. <i>Blood</i> , 2011, 118, 3029-3029.	0.6	0
95	Engraftment Syndrome After Allogeneic Hematopoietic Cell Transplantation: Relationship to Acute Gvhd and Impact on Transplant Outcomes. <i>Blood</i> , 2011, 118, 3013-3013.	0.6	1
96	KIR-Ligand Incompatibility Is Not Associated with Relapse Reduction After Double Umbilical Cord Blood Transplantation,. <i>Blood</i> , 2011, 118, 4150-4150.	0.6	11
97	Altered regulatory T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem cell transplantation. <i>Journal of Clinical Investigation</i> , 2010, 120, 1479-1493.	3.9	212
98	Low Day 30 Total Donor Chimerism After Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Poorer Overall Survival In Myeloid but Not Lymphoid Disorders. <i>Blood</i> , 2010, 116, 1325-1325.	0.6	0
99	Syngeneic Donor Hematopoietic Stem Cell Transplantation Is Associated with High Rates of Engraftment Syndrome. <i>Blood</i> , 2010, 116, 1323-1323.	0.6	0
100	Autologous Peripheral Blood Stem Cell Products from Patients with Hematologic Malignancies Have Increased Frequency of Regulatory T Cells (CD4+FoxP3+ Treg).. <i>Blood</i> , 2008, 112, 2310-2310.	0.6	1
101	GM-CSF Secreting Leukemia Cell Vaccination after Allogeneic Reduced Intensity Hematopoietic Stem Cell Transplantation for Advanced Myeloid Malignancies. <i>Blood</i> , 2008, 112, 825-825.	0.6	1
102	Comparative Outcome of Myeloablative and Reduced Intensity Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2008, 112, 972-972.	0.6	6
103	A Phase I/II Trial of Bortezomib, Tacrolimus and Methotrexate for Prophylaxis of Acute Graft Versus Host Disease after HLA Mismatched Reduced Intensity Transplantation.. <i>Blood</i> , 2008, 112, 1158-1158.	0.6	4
104	Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis. <i>Clinical Cancer Research</i> , 2007, 13, 559-565.	3.2	421
105	Chronic GVHD Is Associated with a BAFF Driven BCR-Activated B Cell Repertoire.. <i>Blood</i> , 2007, 110, 166-166.	0.6	1
106	GM-CSF Secreting Leukemia Cell Vaccinations after Allogeneic Reduced-Intensity Peripheral Blood Stem Cell Transplantation (SCT) for Advanced Myelodysplastic Syndrome (MDS) or Refractory Acute Myeloid Leukemia (AML).. <i>Blood</i> , 2006, 108, 3680-3680.	0.6	1
107	Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. <i>Blood</i> , 2005, 106, 2903-2911.	0.6	430
108	HLA-C Mismatch Is Associated with Inferior Outcome after Unrelated Donor Non-Myeloablative Hematopoietic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 835-835.	0.6	3

#	ARTICLE	IF	CITATIONS
109	Phase III Trial of All-Trans Retinoic Acid (ATRA) vs Daunorubicin (D) and Cytosine Arabinoside (A) as Induction Therapy and ATRA vs Observation as Maintenance Therapy for Children with Newly Diagnosed Acute Promyelocytic Leukemia (APL).. Blood, 2005, 106, 894-894.	0.6	0
110	IL-2 Therapy Promotes the Expansion of Human CD4+CD25+ Regulatory T Cells and Selectively Upregulates the Expression of FOXP3 in T Cells In Vivo.. Blood, 2005, 106, 1257-1257.	0.6	0
111	Relapse of Acute Promyelocytic Leukemia (APL) Is Associated with Increased Methylation of the Retinoic Acid Receptor-Beta2 (RAR $\beta$ 2) Gene Promoter.. Blood, 2004, 104, 1124-1124.	0.6	0